Immunotherapy of Tuberculosis
의약학 > 내과학
( Aldar S Bourinbaiar1 ) , ( Marina V Mezentseva ) , ( Dmitry A Butov ) , ( Peter S Nyasulu ) , ( Yuri V Efremenko ) , ( Vichai Jirathitikal ) , ( Vladimir V Mishchenko ) , ( Galyna A Kutsyna )
대한결핵 및 호흡기학회
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 284(총1페이지)
0y910066.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Tuberculosis is typically caused by Mycobacterium tuberculosis, a symbiotic bacterium found in one third of the world population. There any many factors triggering overt clinical disease in a small proportion of humans. In our view the major role in this process is played by host`s immune response, especially self-directed, destructive inflammation. Conventional che-motherapy produces bactericidal or bacteriostatic effects, but immunopathological changes can be corrected by immunotherapy only. Various attempts have been made to find the optimal immune intervention. Some have shown promising effect, but many have failed. It is commonly held that the field started in 1890-the year Robert Koch announced his tuberculin therapy. In the P?n Ts`ao Kang Mu - classical Chinese materia medica published during Ming dynasty - Li Shi Chen (1518-1593) recom-mended as a remedy for hemoptysis to collect from the sputum "…blood lumps, roast them till they are black, and take then them as a powder." In retrospect, this is perhaps the earliest recorded reference relating to immunotherapy of TB with heat-kil-led mycobacteria. Modern science is obviously geared toward more palatable approach, but without hindsight from often dis-dained empirical evidence no progress can be made. Clinically tested immunotherapies for tuberculosis recently developed by us will be presented in this talk.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.